Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

What started as a spectacular year for the cannabis industry has come crashing down.

Tara Walton/The Canadian Press

All the dreams of a sustained cannabis comeback are quickly getting dashed, and the sell-off is so sharp that the sector’s hardcore supporters have to wonder whether the endless roller coaster is worth it.

What started as a spectacular year for the industry, with the Horizons Marijuana Life Sciences Index surging 140 per cent by early February, has come crashing down. The index is now back to where it started the year, and many of the sector’s stalwarts are faring much worse.

Canopy Growth Corp. has cratered, falling 41 per cent this year, despite the support of wine and spirits giant Constellation Brands Inc., and the combination of Aphria Inc. and Tilray Inc. has done little to support the share price of the merged company.

Story continues below advertisement

Some of the pain can be attributed to market dynamics. Growth stocks caught fire at the start of the year, and cannabis stocks were lumped in, helping to salvage some of their credibility after a disastrous 2020. Fast-forward seven months and many growth stocks have since sold off, as seen in the trading activity of the once-almighty Ark Innovation ETF, which is now down 6 per cent for the year.

Overzealous investor expectations are also playing a significant role again, and hopes of federal legalization in the United States are dissipating, leaving investors staring at many more quarters of red ink. Although Democrats have proposed legislation for cannabis reform now that Joe Biden is in the White House, the meticulous plans they have tabled are likely to get bogged down in the legislative process.

“We believe the comprehensiveness of the draft plan will likely need to see substantial revisions in order to garner enough support to ultimately be implemented into law, which took most of the air out of what was anticipated to be a material catalyst for the sector,” Canaccord Genuity analysts Matt Bottomley and Derek Dley wrote in a recent report for clients.

There are also fears that the Democrats could lose control of the U.S. House of Representatives or the Senate in 2022, which could make it even harder to pass the proposed legislation.

The U.S. itself is not a wasteland for cannabis companies. In fact, some of the American multistate operators – which actually operate within individual states but do not let their operations cross state lines because of the federal rules – are seeing encouraging sales growth. Trulieve Cannabis Corp., which trades on the Canadian Securities Exchange but predominately operates in Florida, is one of the sector’s profitable companies, making it a rarity.

Because so many multistate operators already exist, it will be tough for Canadian-bred companies to compete even if the federal rules eventually change. Given this reality, the domestic operations of these companies carry more weight when investors assess their prospects – and the situation in Canada isn’t pretty.

“We believe the ability to maintain/grow market share in Canada will likely become increasingly difficult … given the saturation of market participants, infrastructure and inventory levels that continue to weigh on virtually all Canadian operators in the space,” Canaccord’s analysts wrote to clients.

Story continues below advertisement

The situation is so fraught that CIBC World Markets analyst John Zamparo recently said the once-venerable Canopy and Aurora Cannabis are likely to bleed red ink for another year, even though both companies have booted their old management teams and spent multiple years cleaning up the old guard’s messes. “We continue to expect at least 12 months until either achieves positive earnings before interest, taxes, depreciation and amortization,” Mr. Zamparo wrote in a recent note to clients.

Because so many Canadian producers are struggling in an oversaturated market, Tilray chief executive Irwin Simon speculated last week that the industry could see some consolidation. “Canadian cannabis stocks have got pretty cheap lately. There’s a point it may make sense to do some other acquisitions out there and buy companies to get share, instead of spending a lot more money going out there and getting share by building awareness with the consumers,” he told an investor conference.

If history is any guide, it may not be enough. Cannabis companies have been merging for years, dating back to Aurora’s 2018 deals for CanniMed Therapeutics Inc. and MedReleaf Corp., and nothing’s changed yet.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies